Literature DB >> 8626256

Laboratory assessment of antibacterial activity of zwitterionic 7-methoxyimino cephalosporins.

J C Pechère1, W Wilson, H Neu.   

Abstract

Zwitterionic 7-methoxyimino cephalosporins (cefpirome, cefepime, cefclidin, DQ2556, FK037 and SCE2787) possess a variable substitution at C3 which contains a quarternary nitrogen. These cephalosporins display low affinities for Class I beta-lactamase and rapid penetration through the outer membrane of Gram-negative bacilli, so that an increased number of periplasmic beta-lactam molecules interact with PBP's per unit of time. As a consequence, the new zitterionic compounds remain active against some, but not all, ceftazidime-resistant Enterobacteriaceae producing high levels of Class I beta-lactamase or Bush type 2b beta-lactamases. Antipseudomonas activities are generally similar to that of ceftazidime except that cefclidin is more active. The new zwitterionic compounds, especially cefpirome and FK037, express greater antistaphylococcal potency than does ceftazidime. A variety of animal models including meningitis and endocarditis have confirmed the potential of these compounds in-vivo. On the basis of structural and antibacterial characteristics, the expression 'forth generation' is acceptable to describe the zwitterionic 7-methoxyimino cephalosporins.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8626256     DOI: 10.1093/jac/36.5.757

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  4 in total

1.  Pharmacokinetics of intravenously and intramuscularly administered cefepime in infants and children.

Authors:  M D Reed; T S Yamashita; C K Knupp; J M Veazey; J L Blumer
Journal:  Antimicrob Agents Chemother       Date:  1997-08       Impact factor: 5.191

2.  Disposition kinetics, bioavailability and renal clearance of cefepime in calves.

Authors:  M M Ismail
Journal:  Vet Res Commun       Date:  2005-01       Impact factor: 2.459

Review 3.  Cefpirome. A review of its antibacterial activity, pharmacokinetic properties and clinical efficacy in the treatment of severe nosocomial infections and febrile neutropenia.

Authors:  L R Wiseman; H M Lamb
Journal:  Drugs       Date:  1997-07       Impact factor: 9.546

4.  Efficacy of piperacillin combined with the Penem beta-lactamase inhibitor BLI-489 in murine models of systemic infection.

Authors:  Peter J Petersen; C Hal Jones; Aranapakam M Venkatesan; Patricia A Bradford
Journal:  Antimicrob Agents Chemother       Date:  2009-02-02       Impact factor: 5.191

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.